Page 1

Eloxx • PHARMACEUTICALS Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Completed underwritten public offering with gross proceeds of $ 66.0 million and uplisting to the Nasdaq Capital Market , significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 • European Commission granted orphan designation for exaluren in ADPKD • Cash and cash equivalents of $ 62.0 million as of June 30 , 2026 , expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease ( ADPKD ) ARLINGTON , Mass . , August 11 , 2026 — Eloxx Pharmaceuticals , Inc. ( Nasdaq : ELOX ) , a clinical - stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases , today reported financial results for the second quarter ended June 30 , 2026 and provided a business update . " The second quarter was transformational for Eloxx . Our public offering , with gross proceeds of $ 66.0 million , together with our uplisting to the Nasdaq Capital Market , has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs , , " said Sumit Aggarwal , President and Chief Executive Officer of Eloxx . " With approximately $ 62.0 million in cash , no outstanding debt , and a clear clinical development plan , we believe we are well positioned to advance our Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome in the third quarter of 2026 and initiate a Phase 2 clinical trial in nonsense mutation ADPKD in 2027. " Financing and Uplisting to Nasdaq $ 66.0 million public offering . The Company completed an underwritten public offering of 2,975,000 shares of common stock at a public offering price of $ 11.00 per share , together with pre - funded warrants to purchase up to 3,025,000 shares of common stock , for gross proceeds of approximately $ 66.0 million and net proceeds of approximately $ 58.3 million , after deducting underwriting discounts and commissions and offering expenses . Uplisting to Nasdaq . In June 2026 , the Company completed its uplisting to the Nasdaq Capital Market , where its common stock began trading under the symbol " ELOX . " Recent Business Highlights Exaluren in nonsense mutation Alport syndrome ( NMAS ) . The Company received clearance under its Investigational New Drug application from the U.S. Food and Drug Administration ( FDA ) to proceed with a Phase 2b clinical trial of exaluren in patients with NMAS and plans to initiate the trial in the third quarter of 2026. The Company anticipates topline data from the initial 16 - week placebo- controlled portion of the study by mid - 2027 , with the final readout by the end of 2027. Exaluren has received orphan drug designation from the FDA and European Commission for the treatment of Alport syndrome .